DOP2021000215A - Tratamiento de la cefalea usando anticuerpo anti-cgrp - Google Patents

Tratamiento de la cefalea usando anticuerpo anti-cgrp

Info

Publication number
DOP2021000215A
DOP2021000215A DO2021000215A DO2021000215A DOP2021000215A DO P2021000215 A DOP2021000215 A DO P2021000215A DO 2021000215 A DO2021000215 A DO 2021000215A DO 2021000215 A DO2021000215 A DO 2021000215A DO P2021000215 A DOP2021000215 A DO P2021000215A
Authority
DO
Dominican Republic
Prior art keywords
cgrp antibody
headache treatment
headache
treatment
cgrp
Prior art date
Application number
DO2021000215A
Other languages
English (en)
Spanish (es)
Inventor
Schaeffler Barbara
Mehta Lahar
K Cady Roger
T L Smith Jeffrey
Hirman Joseph
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of DOP2021000215A publication Critical patent/DOP2021000215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DO2021000215A 2019-05-02 2021-10-19 Tratamiento de la cefalea usando anticuerpo anti-cgrp DOP2021000215A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US201962872989P 2019-07-11 2019-07-11
PCT/US2020/012781 WO2020146527A1 (en) 2019-01-08 2020-01-08 Acute treatment and rapid treatment of headache using anti-cgrp antibodies
PCT/US2020/018702 WO2020222892A1 (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
DOP2021000215A true DOP2021000215A (es) 2021-11-21

Family

ID=73028680

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000215A DOP2021000215A (es) 2019-05-02 2021-10-19 Tratamiento de la cefalea usando anticuerpo anti-cgrp

Country Status (20)

Country Link
US (1) US20220251178A1 (https=)
EP (1) EP3962522A4 (https=)
JP (2) JP2022533030A (https=)
KR (1) KR20220004053A (https=)
CN (1) CN113811326A (https=)
AU (1) AU2020267107B2 (https=)
BR (1) BR112020027063A2 (https=)
CA (1) CA3133571A1 (https=)
CL (1) CL2021002866A1 (https=)
DO (1) DOP2021000215A (https=)
EA (1) EA202192865A1 (https=)
GE (2) GEP20257803B (https=)
IL (1) IL287759A (https=)
JO (1) JOP20210247A1 (https=)
MA (1) MA55815A (https=)
MX (1) MX2021013426A (https=)
PH (1) PH12021552422A1 (https=)
SG (1) SG11202110637RA (https=)
WO (1) WO2020222892A1 (https=)
ZA (1) ZA202106627B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
KR20240058082A (ko) 2021-09-15 2024-05-03 하. 룬드벡 아크티에셀스카브 항-cgrp 항체 투약 및 스크리닝 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
AU2015230933B2 (en) * 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
KR20220004053A (ko) 2022-01-11
MA55815A (fr) 2022-03-09
CL2021002866A1 (es) 2022-06-17
AU2020267107A1 (en) 2021-10-07
EP3962522A4 (en) 2023-07-19
BR112020027063A2 (pt) 2021-11-16
ZA202106627B (en) 2025-12-17
CA3133571A1 (en) 2020-11-05
IL287759A (en) 2022-01-01
JP2026016471A (ja) 2026-02-03
GEP20257803B (en) 2025-10-10
EA202192865A1 (ru) 2022-02-14
PH12021552422A1 (en) 2022-07-11
WO2020222892A1 (en) 2020-11-05
GEAP202515803A (en) 2025-06-10
EP3962522A1 (en) 2022-03-09
JOP20210247A1 (ar) 2023-01-30
JP2022533030A (ja) 2022-07-21
US20220251178A1 (en) 2022-08-11
CN113811326A (zh) 2021-12-17
MX2021013426A (es) 2021-12-10
SG11202110637RA (en) 2021-10-28
AU2020267107B2 (en) 2026-04-09

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CR20210373A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2025003354A (es) Anticuerpos que se unen a 5t4
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CO2022000270A2 (es) Inhibidores de enzimas
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2021000531A1 (es) Métodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2021012848A (es) Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.
MX2022000393A (es) Metodo.
MX2018001528A (es) Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña.